22. Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and
management of adolescent patients with HAIR-AN syndrome.
ScientificWorldJournal. 2004;4:507-511.
23. Feng W, Jia YY, Zhang DY, Shi HR. Management of polycystic ovarian
syndrome with Diane-35 or Diane-35 plus metformin. Gynecol Endocrinol.
2016;32(2):147-150.
24. Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study
to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over
metformin in patients with polycystic ovarian syndrome. Diabetes Metab
Syndr. 2016;10(1 Suppl 1):S95-98.
25. Fruzzetti F, Perini D, Russo M, et al. Comparison of two insulin sensitizers,
metformin and myo-inositol, in women with polycystic ovary syndrome
(PCOS). Gynecol Endocrinol. 2017;33(1):39-42.
26. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of
simvastatin and metformin on polycystic ovary syndrome after six months
of treatment. J Clin Endocrinol Metab. 2011;96(11):3493-3501.
27. Tehrani HG, Mostajeran F, Shahsavari S. The effect of calcium and
vitamin D supplementation on menstrual cycle, body mass index and
hyperandrogenism state of women with poly cystic ovarian syndrome.
J Res Med Sci. 2014;19(9):875-880.
28. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin
treatment is effective in obese teenage girls with PCOS. Hum Reprod.
2006;21(9):2252-2256.
29. Oppelt PG, Mueller A, Jentsch K, et al. The effect of metformin treatment for
2 years without caloric restriction on endocrine and metabolic parameters
in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes.
2010;118(9):633-637.
30. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on
hyperandrogenism in women with polycystic ovarian syndrome. Gynecol
Endocrinol. 2003;17(1):51-56.
31. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F.
Sensitization to insulin induces ovulation in nonobese adolescents with
anovulatory hyperandrogenism. J Clin Endocrinol Metab. 2001;86(8):3595-
3598.
32. Ibanez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls
to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia,
and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab.
2000;85(10):3526-3530.
33. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment
with metformin added to hypocaloric diet on body composition, fat
distribution, and androgen and insulin levels in abdominally obese women
with and without the polycystic ovary syndrome. J Clin Endocrinol Metab.
2000;85(8):2767-2774.
34. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary
syndrome. Eur J Endocrinol. 2002;147(2):217-221.
35. Onalan G, Goktolga U, Ceyhan T, et al. Predictive value of glucose-insulin ratio
in PCOS and profile of women who will benefit from metformin therapy:
obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol.
2005;123(2):204-211.
36. Al-Ozairi E, Quinton R, Advani A. Therapeutic response to metformin in
an underweight patient with polycystic ovarian syndrome. Fertil Steril.
2008;90(4):1197.e1191-1194.
37. Israni P, Panat M. Proximal Tibial Epiphysis Injury (Flexion Type, Salter-Harris
Type 1). J Orthop Case Rep. 2016;6(4):62-65.
38. Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in
women with polycystic ovary syndrome: a prospective randomized, doubleblind,
placebo-controlled trial. J Clin Endocrinol Metab. 2006;91(3):946-952.
39. Fux Otta C, Wior M, Iraci GS, et al. Clinical, metabolic, and endocrine
parameters in response to metformin and lifestyle intervention in women
with polycystic ovary syndrome: a randomized, double-blind, and placebo
control trial. Gynecol Endocrinol. 2010;26(3):173-178.
40. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features,
endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary
syndrome: a randomized, double-blind, placebo-controlled 6-month trial,
followed by open, long-term clinical evaluation. J Clin Endocrinol Metab.
2000;85(1):139-146.
41. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin
administration on sex hormone-binding globulin, androgens, and insulin in
hirsute and obese women. J Clin Endocrinol Metab. 1995;80(7):2057-2062.
42. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, et al. Metformin
versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese
women with polycystic ovary syndrome: a randomized study. J Clin
Endocrinol Metab. 2003;88(1):148-156.
43. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of
spironolactone with metformin in the management of polycystic ovary
syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004;89(6):2756-
2762.44. Diri H, Karaburgu S, Acmaz B, et al. Comparison of spironolactone and
spironolactone plus metformin in the treatment of polycystic ovary
syndrome. Gynecol Endocrinol. 2016;32(1):42-45.
45. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or
antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
J Clin Endocrinol Metab. 2003;88(9):4116-4123.
46. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Comparison
of ethinyl-estradiol plus cyproterone acetate versus metformin effects on
classic metabolic cardiovascular risk factors in women with the polycystic
ovary syndrome. J Clin Endocrinol Metab. 2007;92(7):2453-2461.
47. Roth LW, Huang H, Legro RS, et al. Altering hirsutism through ovulation
induction in women with polycystic ovary syndrome. Obstet Gynecol.
2012;119(6):1151-1156.
48. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the
polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883-
896.
49. Ibanez L, Diaz M, Sebastiani G, et al. Treatment of androgen excess in
adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose
pioglitazone-flutamide-metformin. J Clin Endocrinol Metab. 2011;96(11):3361-
3366.
50. Yilmaz M, Karakoc A, Toruner FB, et al. The effects of rosiglitazone and
metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Gynecol Endocrinol. 2005;21(3):154-160.
51. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum
androgen and insulin resistance to metformin and pioglitazone in obese,
insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol
Metab. 2005;90(3):1360-1365.
52. Oner G, Muderris, II. Clinical, endocrine and metabolic effects of metformin
vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet
Gynecol Reprod Biol. 2011;159(1):127-131.
53. Rezvanian H, Adibi N, Siavash M, et al. Increased insulin sensitivity by
metformin enhances intense-pulsed-light-assisted hair removal in patients
with polycystic ovary syndrome. Dermatology. 2009;218(3):231-236.
54. Dravecka I, Figurova J, Javorsky M, et al The effect of alfacalcidiol and
metformin on phenotype manifestations in women with polycystic ovary
syndrome - a preliminary study. Physiol Res. 2016;65(5):815-822.
55. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebocontrolled
trial of intensive lifestyle modification and/or metformin therapy
in overweight women with polycystic ovary syndrome: a pilot study. Fertil
Steril. 2004;82(2):421-429.
56. Balak DM, van Doorn MB, Arbeit RD, et al. IMO-8400, a toll-like receptor 7,
8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized,
placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Clin Immunol. 2017;174:63-72.
57. Fitzgerald DC, Meade KG, McEvoy AN, et al. Tumour necrosis factoralpha
(TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in
and interleukin-8 (IL-8) release from bovine mammary epithelial cells. Vet
Immunol Immunopathol. 2007;116(1-2):59-68.
58. Andersen R, Jemec GB. New treatment strategies for hidradenitis
suppurativa. Drugs Today (Barc). 2016;52(8):439-451.
59. Ingram JR. Interventions for Hidradenitis Suppurativa: Updated Summary of
an Original Cochrane Review. JAMA Dermatol. 2017;153(5):458-459.
60. Ghiasi M, Ebrahimi S, Lajevardi V, Taraz M, Azizpour A. Efficacy and safety
of pioglitazone plus phototherapy vs. phototherapy in patients with plaque
type psoriasis: a double blinded randomized controlled trial. J Dermatolog
Treat. 2018:1-15.
61. Mansour HH, El Kiki SM, Galal SM. Metformin and low dose radiation
modulates cisplatin-induced oxidative injury in rat via PPAR-gamma and
MAPK pathways. Arch Biochem Biophys. 2017;616:13-19.
62. El-Gharabawy RM, Ahmed AS, Al-Najjar AH. Mechanism of action and
effect of immune-modulating agents in the treatment of psoriasis. Biomed
Pharmacother. 2017;85:141-147.
63. Verma N, Jain V, Birla S, Jain R, Sharma A. Growth and hormonal profile from
birth to adolescence of a girl with aromatase deficiency. J Pediatr Endocrinol
Metab. 2012;25(11-12):1185-1190.
64. Lee PJ, Cranston I, Amiel SA, et al. Effect of metformin on glucose disposal
and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Horm
Res. 1997;48(2):88-92.
65. Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral
contraceptives, and lifestyle modification on polycystic ovary syndrome in
obese adolescent women in two randomized, placebo-controlled clinical
trials. J Clin Endocrinol Metab. 2008;93(11):4299-4306.
66. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial
evaluating response to metformin versus standard therapy in the treatment
of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab.
2005;18(8):761-768.
